Möchten Sie immer auf dem neuesten Stand bleiben?

ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

Phoenix Energy launches an updated Bondholder Portal with enhanced usability and new features to support its growing base of 6,000+ investors.

BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and...

Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash...

Revenue Growth Driving Group to Record EBITDA •Revenue of $186.5 million with organic revenue growth of 6.2%•Record Adjusted EBITDA of $45.4 million, up 17.7% year over year, achieved at a margin of...

A Mobilicom Tier-1 defense customer won a U.S. Department of War (DoW) Program of Record, indicating a potential production scale orders for the next 5 years  Cash and cash equivalents surge 120% to...

AtlasClear Holdings Announces Commencement of Dawson James Clearing Operations

Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ...

BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...

SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated...